GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Valuation Rank

Cardiol Therapeutics (TSX:CRDL) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cardiol Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Valuation Rank
Comparable Companies
XCNQ:GRIN XCNQ:INNO TSXV:LOVE TSXV:ZYUS TSXV:RX TSXV:DB XCNQ:HUGE TSX:CWEB TSX:MDP TSX:CPH ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
CRDL:USA CT9:Germany
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Website
https://www.cardiolrx.com
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Executives
Guillermo Torre Senior Officer